Search for a command to run...
Cresanto Global Ltd. lags significantly behind its peers in key financial metrics, reflecting its weak market position and operational challenges. The analysis reveals that while some peers demonstrate strong profitability and growth, Cresanto's performance metrics indicate financial distress, making it an unappealing investment option at this time.
Stocks | CMP | Market Cap | P/E | ROCE (%) | Debt/Equity |
---|---|---|---|---|---|
Cresanto Global Ltd. | ₹3.65 | ₹1.56Cr | -8.67 | - | - |
SUNPHARMA | ₹1,563.35 | ₹3,75,099.26Cr | 87.59 | 17.60% | 0.04 |
DIVISLAB | ₹6,091.05 | ₹1,61,698.50Cr | 73.20 | 16.46% | - |
CIPLA | ₹1,587.60 | ₹1,28,217.27Cr | 23.73 | 22.77% | 0.01 |
TORNTPHARM | ₹3,581.55 | ₹1,21,215.77Cr | 61.53 | 24.28% | 0.57 |
DRREDDY | ₹1,280.30 | ₹1,06,835.27Cr | 15.50 | 26.86% | 0.07 |
MANKIND | ₹2,518.95 | ₹1,03,926.59Cr | 55.18 | 28.38% | 0.02 |